Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 5/20 | 1.00 |
| ▸ | CA6 | P23280 | 5/20 | 1.00 |
| ▸ | CA7 | P43166 | 5/20 | 1.00 |
| ▸ | CA9 | Q16790 | 5/20 | 1.00 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 1.00 |
| ▸ | CA5B | Q9Y2D0 | 5/20 | 1.00 |
| ▸ | CA2 | P00918 | 4/20 | 1.00 |
| ▸ | CA4 | P22748 | 4/20 | 1.00 |
| ▸ | CA5A | P35218 | 4/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 3/20 | 1.00 |
| ▸ | CA3 | P07451 | 3/20 | 1.00 |
| ▸ | F13A1 | P00488 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 1.00 |
| ▸ | THPO | P40225 | 2/20 | 1.00 |
| ▸ | CA1 | P00915 | 2/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | PKM | P14618 | 1/20 | 1.00 |
| ▸ | TSHR | P16473 | 1/20 | 1.00 |
| ▸ | MTOR | P42345 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.93 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3165201 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermidine SCHEMBL288987 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL3175232 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL431884 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL288605 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermine SCHEMBL5802297 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermidine SCHEMBL15618 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| Spermidine SCHEMBL6253721 | 1.00 | CA12 (1.00) | CA12CA6CA7CA9CA14 | |
| SCHEMBL4861043 | 0.97 | CA12 (0.93) | CA12CA6CA7CA9CA14 | |
| Spermidine SCHEMBL573651 | 0.97 | LMNA (1.00) | CA12CA6CA7CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 53 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210069263-A1 | BACTERIA-COMPRISING COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING GASTROINTESTINAL, METABOLIC AND/OR OTHER DISEASES | UNIV WAGENINGEN (NL) | 2021-03-11 | — | — | US | claimed |
| EP-3242957-B1 | BACTERIA-COMPRISING COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING GASTROINTESTINAL, METABOLIC AND/OR OTHER DISEASES | UNIV WAGENINGEN (NL) | 2020-03-11 | — | — | EP | claimed |
| US-20180353552-A1 | BACTERIA-COMPRISING COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING GASTROINTESTINAL, METABOLIC AND/OR OTHER DISEASES | WAGENINGEN UNIVERSITEIT (NL) | 2018-12-13 | — | — | US | claimed |
| EP-3242957-A1 | BACTERIA-COMPRISING COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING GASTROINTESTINAL, METABOLIC AND/OR OTHER DISEASES | Wageningen Universiteit (NL) | 2017-11-15 | — | — | EP | claimed |
| WO-2016110585-A1 | BACTERIA-COMPRISING COMPOSITIONS AND METHODS OF USING THE SAME FOR TREATING AND/OR PREVENTING GASTROINTESTINAL, METABOLIC AND/OR OTHER DISEASES | WAGENINGEN UNIVERSITEIT (NL) | 2016-07-14 | — | — | WO | claimed |
| EP-4368254-A2 | MODULATION OF THE GUT MICROBIOME TO TREAT MENTAL DISORDERS OR DISEASES OF THE CENTRAL NERVOUS SYSTEM | Holobiome, Inc. (US) | 2024-05-15 | — | — | EP | disclosed |
| EP-4346857-A1 | INSULIN-SENSITIZING AGENT AND BUTYRATE-PRODUCING BACTERIUM | Caelus Pharmaceuticals B.V. (NL) | 2024-04-10 | — | — | EP | disclosed |
| US-11667927-B2 | Chromobacterium subtsugae genome | PRO FARM GROUP, INC. (US) | 2023-06-06 | — | — | US | disclosed |
| US-11414463-B2 | Polypeptide and immune modulation | 4D PHARMA RESEARCH LIMITED (GB) | 2022-08-16 | — | — | US | disclosed |
| US-20220040242-A1 | MODULATION OF THE GUT MICROBIOME TO TREAT MENTAL DISORDERS OR DISEASES OF THE CENTRAL NERVOUS SYSTEM | HOLOBIOME, INC. | 2022-02-10 | — | — | US | disclosed |
| US-20210388378-A1 | Chromobacterium Subtsugae Genome | MARRONE BIO INNOVATIONS, INC. (US) | 2021-12-16 | — | — | US | disclosed |
| US-11130966-B2 | Chromobacterium subtsugae genome | MARRONE BIO INNOVATIONS, INC. (US) | 2021-09-28 | — | — | US | disclosed |
| EP-0954596-A1 | ENHANCED PRODUCTION OF TAXANES BY CELL CULTURES OF $i(TAXUS) SPECIES | PHYTON, INC. (US) | 1999-11-10 | — | — | EP | disclosed |
| WO-1997044476-A1 | ENHANCED PRODUCTION OF TAXANES BY CELL CULTURES OF TAXUS SPECIES | PHYTON, INC. (US) | 1997-11-27 | — | — | WO | disclosed |
| US-5189025-A | Administering amino acid mixture | BOARD OF REGENETS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1993-02-23 | — | — | US | disclosed |
| US-5162373-A | Gut Atrophy Prevention, Ornithine, Methionine | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1992-11-10 | — | — | US | disclosed |
| US-4988724-A | Anticarcinogenic agents, antitumor agents, amino acids and citrulline and ornithine; arginine-free; antitumor and -carcinogenic agents | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1991-01-29 | — | — | US | disclosed |
| US-4859452-A | ADMINISTERING MIXTURE OF AMINO ACID AND POLYAMINE | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 1989-08-22 | — | — | US | disclosed |
| US-4550078-A | ENZYMATIC OXIDATIVE DECOMPOSITION | AMANO SEIYAKU KABUSHIKI KAISHA (JP) | 1985-10-29 | — | — | US | disclosed |
| US-4499072-A | Process for treating diseases with ODC inhibitors | MERRELL DOW PHARMACEUTICALS INC. (US) | 1985-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220040242-A1 | MODULATION OF THE GUT MICROBIOME TO TREAT MENTAL DISORDERS OR DISEASES OF THE CENTRAL NERVOUS SYSTEM | GABBR1, GABBR2, GABRR2 | CA12 2148/4885CA6 1925/4885CA7 3227/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.